INBX

Inhibrx Biosciences Inc

Add to Watchlist

Advanced Chart

21.600

-0.32(-1.460%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

22.240

Open

21.600

VWAP

21.81

Vol

58.81K

Mkt Cap

312.68M

Low

21.3712

Amount

1.28M

EV/EBITDA(TTM)

Total Shares

14.48M

199.44M

EV/OCF(TTM)

P/S(TTM)

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q1

-2.650

-6.69%

-3.120

+116.67%

Estimates Revision

The market is revising No Change the revenue expectations for Inhibrx, Inc. (INBX) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 75.32%.

Revenue Estimates for FY2024

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2024

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+75.32%

In Past 3 Month

1 Analyst Rating

-30.56% Downside

Wall Street analysts forecast INBX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBX is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

-30.56% Downside

Current: 21.600

Low

15.00

Averages

15.00

High

15.00

-30.56% Downside

Current: 21.600

Low

15.00

Averages

15.00

High

15.00

Citizens Capital Markets

Reni Benjamin

Hold

Reiterates

n/a

2025-03-18

Reason

Citizens Capital Markets

Reni Benjamin

Price Target

n/a

2025-03-18

Reiterates

Hold

Reason

JMP Securities

Reni Benjamin

Hold

Reiterates

n/a

2025-01-22

Reason

JMP Securities

Reni Benjamin

Price Target

n/a

2025-01-22

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Inhibrx Biosciences Inc (INBX.O) is -2.03, compared to its 5-year average forward P/E of -0.65. For a more detailed relative valuation and DCF analysis to assess Inhibrx Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.65

Current PE

-2.03

Overvalued PE

0.09

Undervalued PE

-1.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00